| Document |
Document Title |
|
WO/2007/081479A1 |
Diraromatic amine derivatives having the general formula: (I) wherein n is from 0 to 5; m is from 0 to 4; each R substituent is independently hydrogen or a straight or branched C1-C32 alkyl group or alkenyl group or two R substituents to...
|
|
WO/2007/079186A2 |
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosc...
|
|
WO/2007/078523A2 |
The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employe...
|
|
WO/2007/074477A2 |
The invention provides two crystalline forms A and B of the skeletal muscle relaxant and anxiolytic agent, Metaxalone of formula (I), and a process for preparation thereof. The two crystalline forms A and B are bioavailable. The inventio...
|
|
WO/2007/075870A2 |
The application provides a process for the preparation of taxane derivatives and intermediates useful in such processes.
|
|
WO/2007/073699A1 |
5,5'-linked 1,1'-biphenyl axial chiral ligands in the field of chemical engineering technique are disclosed. The present ligands have both central chirality of oxazoline and axial chirality of biphenyl. The present ligands are expected t...
|
|
WO/2007/073296A1 |
The present invention relates to novel thiazole and oxazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a ...
|
|
WO/2007/069773A1 |
The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene rin...
|
|
WO/2007/068815A2 |
The invention concerns compounds of formula (I) wherein: X represents a -C-, -SO2-, -C-N(R5)-C-N(R5)- group; Y represents an oxygen atom or a sulphur atom; R1 represents a hydrogen atom or a C1-C4 alkyl group; R2 represents a C1-C7 alkyl...
|
|
WO/2007/065821A1 |
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula (I) and pharmace...
|
|
WO/2007/066617A1 |
Disclosed is a method for producing an azoline compound represented by the general formula (3) below, which is characterized in that a carboxylic acid or a carboxylic acid derivative represented by the general formula (1) below is reacte...
|
|
WO/2007/065828A1 |
The present invention relates to compounds of formula (I) wherein A, X, R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula I and phar...
|
|
WO/2007/067501A1 |
A process for the enantio selective synthesis of an (S)- or (R)- l-[2- dimethylamino)-l-(methoxyphenyl)ethyl]cyclohexanol and analogues or salt thereof are described. The method involves the steps of (a) reacting an (S) or (R) 4- benzylo...
|
|
WO/2007/063789A1 |
Disclosed are a compound having a strong COMT inhibitory effect and represented by the general formula (I) below, a pharmacologically acceptable salt thereof, a pharmaceutical composition containing either of them, and uses of them. (I) ...
|
|
WO/2007/063839A1 |
Disclosed is a cyclohexane derivative represented by the formula (I), which can bind specifically to an NR1/NR2B receptor and therefore can be used as an analgesic agent (a therapeutic agent for pain): (I) wherein A1 represents a (substi...
|
|
WO/2007/064818A1 |
The present invention provides an isolated linezolid impurity, desfluoro linezolid, the preparation thereof and its use as a reference standard.
|
|
WO/2007/064749A1 |
This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, T...
|
|
WO/2007/064316A1 |
The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. ...
|
|
WO/2007/063946A1 |
It is intended to provide a diagnostic which specifically binds to an amyloid aggregate or deposit and thus enables the visualization or quantification of a disease caused by the amyloid aggregation and/or deposition. Namely, a compound ...
|
|
WO/2007/060121A1 |
The present invention relates to Indanyl- and Tetrahydronaphthyl-amino-azoline compounds of formula (I) wherein the variables R1 and R2 are as defined in description. The invention relates also to methods of combating or controlling inse...
|
|
WO/2007/060526A1 |
The invention relates to substituted azacycloalkaπe compounds useful in treating conditions of the Central Nervous System (CNS); a pharmaceutical composition comprising same; a method of treating such conditions and of treating conditio...
|
|
WO/2007/062316A2 |
A compound of Formula I is disclosed, in which R is a substituent containing a hydrogen bond-forming atom within three atoms from the ring carbon to which the substituent is bonded; X is CH2, 0, S or NR1, wherein Rl is a hydrocarbyl grou...
|
|
WO/2007/056366A2 |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated R...
|
|
WO/2007/056496A1 |
The invention provides compounds (I) pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activate...
|
|
WO/2007/055929A1 |
Polyfunctional cyclic carbonates provide a useful additional monomer for energy-initiated cationic copolymerisation with such other monomers and oligomers as epoxides and oxetanes.
|
|
WO/2007/056469A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2007/052843A1 |
Disclosed is a FXR inhibitor comprising a compound represented by the formula (I') or a salt or a prodrug of the compound or salt: wherein each symbol is as defined in the description. The FXR inhibitor has an excellent FXR-inhibiting ef...
|
|
WO/2007/048595A1 |
The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals.
|
|
WO/2007/047306A1 |
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal depositi...
|
|
WO/2007/042816A1 |
There is provided the use of a compound of formula (I),wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a ...
|
|
WO/2007/043400A1 |
Disclosed are: a novel compound having one or both of a xanthine oxidase inhibitory activity and an uric acid excretion promoting activity; a pharmaceutical composition comprising the compound as an active ingredient; use of the compound...
|
|
WO/2007/043401A1 |
Disclosed are: a novel compound having a xanthine oxidase inhibitory activity and an uric acid excretion promoting activity; and a pharmaceutical composition comprising the compound as an active ingredient. The compound is a nitrogenated...
|
|
WO/2007/037010A1 |
It is intended to provide a novel compound having an excellent agonism to PPARs α/γ and desirable properties as a drug. An agonist to peroxisome proliferator-activated receptors α/γ which is represented by the general formula (I) (wh...
|
|
WO/2007/037187A1 |
A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represent...
|
|
WO/2007/034035A1 |
The invention relates to sulphonamide derivatives of formula (I), where Rc is selected from a group consisting of dialkylamino, NO2, CN, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkanoyl, oxazol-2-yl, oxazolylaminocar...
|
|
WO/2007/033266A2 |
Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-
dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of m...
|
|
WO/2007/032028A1 |
The present invention encompasses; the novel substituted heterocyclic compounds represented by formula (I) or their pharmaceutically acceptable salts, wherein the substituents in formula (I) have the meanings as defined in the specificat...
|
|
WO/2007/033002A1 |
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: (F) where the definitions of the variables Q, L1, , L2, M, X, L3, and A are provided ...
|
|
WO/2007/030385A2 |
An improved method of preparing oxazolidine protected aminodiol compounds is disclosed. These compounds are useful intermediates in processes for making Florfenicol.
|
|
WO/2007/030386A2 |
An improved method of preparing oxazolidine protected aminodiol compounds is disclosed. These compounds are useful intermediates in processes for making Florfenicol.
|
|
WO/2007/029036A2 |
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or stereoisomers thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cel...
|
|
WO/2007/025709A2 |
The invention relates to novel diamines of the formula (I) in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments ...
|
|
WO/2007/026753A1 |
Disclosed is a method for producing a 2-oxazoline analogue or a 1,3-oxazine analogue represented by the general formula (3) below wherein 1,2-aminoalcohol or 1,2-aminothiol is reacted with α,α-dihaloamine. (3) (In the formula, n is 0 o...
|
|
WO/2007/023141A1 |
The present invention relates to N-oxides of certain piperazine and piperidine derivatives and to methods for the preparation of these compounds. The invention also relates to the use of compounds disclosed herein for the manufacture of ...
|
|
WO/2007/020936A1 |
It is intended to provide a 1,6-β-glucan synthase inhibitor which strongly inhibits proliferation and has a high safety. It is intended to provide a compound which can specifically or selectively expressing an antifungal action on a bro...
|
|
WO/2007/017687A2 |
A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; L' is a single bond, -O- or -C(=O)-; A is selected from the group consisting...
|
|
WO/2007/017414A1 |
Dicyanoalkane compounds of formula (I), wherein R1, R2, R3,R4 and A are defined as in the description, or the enantiomers or diastereomers or salts thereof are subject matter of the present invention. Further also processes and intermedi...
|
|
WO/2007/017546A2 |
The invention relates to a method of obtaining tryptamine derivatives (I), wherein R is a radical of a heterocycle, comprising the decarboxylation of the corresponding derivative of 3-(2-aminoethyl)-1H-indole carboxylic acid and the subs...
|
|
WO/2007/017669A1 |
Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiritory tract diseases: wherein (i) R1 is C1-C6-alkyl or hydrogen; and R2 is hydrogen or a group -R7, -Z-Y-...
|
|
WO/2007/016979A2 |
The present invention relates to compounds of the general formula (III) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof, Formula (III) wherein R3 is H...
|
